Broxyquinoline | Dibromoxyquinoline | NSC-1810 | CAS#521-74-4 | Tetrahydrofolate Dehydrogenase Inhibitor

Broxyquinoline
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329213

CAS#: 521-74-4

Description: Broxyquinoline, also known as Dibromoxyquinoline and NSC-1810, is a tetrahydrofolate dehydrogenase inhibitor used to treat vaginitis. Broxyquinoline induces VEGF transcription and shows angiogenic effects, stabilizes HIF-1α, and shows antiprotozoal and antifungal effects in vivo.

Chemical Structure

Broxyquinoline

CAS# 521-74-4

Instruction

Theoretical Analysis

MedKoo Cat#: 329213
Name: Broxyquinoline
CAS#: 521-74-4
Chemical Formula: C9H5Br2NO
Exact Mass: 300.87
Molecular Weight: 302.953
Elemental Analysis: C, 35.68; H, 1.66; Br, 52.75; N, 4.62; O, 5.28

Price and Availability

Size	Price	Availability	Quantity
2g	USD 150
5g	USD 250
10g	USD 450
20g	USD 650
50g	USD 950
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Broxyquinoline; NSC 1810; NSC-1810; NSC1810; Dibromoxyquinoline; UCB 5055; UCB-5055; UCB5055; Paramibe; Brodiar

IUPAC/Chemical Name: 5,7-dibromoquinolin-8-ol

InChi Key: ZDASUJMDVPTNTF-UHFFFAOYSA-N

InChi Code: InChI=1S/C9H5Br2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H

SMILES Code: OC1=C2N=CC=CC2=C(Br)C=C1Br

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 302.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Swain R, Bapna JS. Impairment of exercise tolerance due to broxyquinoline-brobenzoxaldine combination. Hum Toxicol. 1986 Jan;5(1):63-4. PubMed PMID: 3081430.

2: Swain R, Bapna JS, Das AK, Chandrasekar S, Swaminathan RP, Bosco B, Veliath S, Thombre DP. A study on the neurotoxicity of broxyquinoline and brobenzoxaldine combination in therapeutic doses. Hum Toxicol. 1986 Jan;5(1):35-41. PubMed PMID: 3081428.

3: Edibam BM. Comparative study of the efficacy of chloramphenicol and a combination of chloramphenicol, broxyquinoline and brobanzoxaldine in the treatment of enteric fever. Indian Pediatr. 1975 Jul;12(7):587-91. PubMed PMID: 810421.

4: Rao SR, Rajyalaxmi K, Murthy KJ, Chandrasekhar VP. Anti-fungal activity of broxyquinoline and brobenzoxaldine. J Assoc Physicians India. 1973 Mar;21(3):295-8. PubMed PMID: 4792779.

5: Shah AP, Phatak AT. A clinical trial of broxyquinoline--brobenzoxalidine in childhood diarrhoea. Indian J Pediatr. 1973 Mar;40(302):83-92. PubMed PMID: 4585812.

6: Strandvik B, Zetterström R. Amaurosis after broxyquinoline. Lancet. 1968 Apr 27;1(7548):922-3. PubMed PMID: 4171525.

7: Hazra SK, Ghosh S, Kundu SK, Chaudhuri S. Therapeutic trial of a combination of broxyquinoline and brobenzoxaldine in the treatment of leprosy. Lepr India. 1979 Oct;51(4):505-10. PubMed PMID: 118304.

8: Sharma CS. Letter: Effect of broxyquinoline and broxaldine in leprosy. Lancet. 1975 Feb 15;1(7903):405. PubMed PMID: 46561.

9: Bengtsson K, Vikrot O. [Retrograde amnesia after broxyquinoline intake]. Lakartidningen. 1972 Jun 12;69:Suppl 2:14-6. Swedish. PubMed PMID: 4645695.

10: Majumdar M, Majumdar H. Broxyquinoline and brobenzoxaldine with belladonna in childhood diarrhoeas. Indian Pediatr. 1971 Feb;8(2):65-7. PubMed PMID: 5560455.

11: Manchanda SS, Grover L, Bhushan S, Lal H. Broxyquinoline and brobenzoxalidine suspension (Intestopan-AI 307) in childhood diarrhoea. A clinical trial on 533 children. Indian J Pediatr. 1970 May;37(268):177-84. PubMed PMID: 4933138.

12: Edibam E, Vegad J. Chloramphenicol with streptomycin, chloramphenicol with broxyquinoline and brobenzoxaldine suspension in diarrhoeas. Indian Pediatr. 1970 May;7(5):281-5. PubMed PMID: 4920675.

13: Rodriguez LA, Close JA. The metabolism of the 5-7-dibromo-8-hydroxyquinoline (broxyquinoline) in man. Biochem Pharmacol. 1968 Aug;17(8):1647-53. PubMed PMID: 5672825.

14: Liu YC, Chen ZF, Song XY, Peng Y, Qin QP, Liang H. Synthesis, crystal structure, cytotoxicity and DNA interaction of 5,7-dibromo-8-quinolinolato-lanthanides. Eur J Med Chem. 2013 Jan;59:168-75. doi: 10.1016/j.ejmech.2012.11.001. PubMed PMID: 23220645.

15: Fritzler JM, Zhu G. Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP). J Antimicrob Chemother. 2012 Mar;67(3):609-17. doi: 10.1093/jac/dkr516. PubMed PMID: 22167242; PubMed Central PMCID: PMC3276058.

Your view history

Broxyquinoline featured